Compare · ABIO vs ORKA

ABIO vs ORKA

Side-by-side comparison of ARCA biopharma Inc. (ABIO) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ABIO and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • ORKA carries a market cap of $6.50B.
  • ORKA has hit the wire 10 times in the past 4 weeks while ABIO has been quiet.
  • ORKA has more recent analyst coverage (11 ratings vs 0 for ABIO).
MetricABIOORKA
Company
ARCA biopharma Inc.
Oruka Therapeutics Inc.
Price
-
-
Market cap
-
$6.50B
1M return
-
+18.08%
1Y return
-
+221.05%
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
0
10
Recent ratings
0
11
ABIO

ARCA biopharma Inc.

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Latest ABIO

Latest ORKA